SLDB today
$7.60+$0.43 (+6.00%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minBearish
5 minStrong Bearish
Daily trend turns up above $7.04
Key levels
Resistance$9.03
Resistance$8.16
Support$7.54
Support$6.65
Latest news & SEC filings
DealCircio and Solid Biosciences partner on gene therapy for genetic heart disease
DealCircio and Solid Biosciences team up on heart gene therapy research
AnalystWilliam Blair starts Solid Biosciences coverage with Buy rating
AnalystWilliam Blair starts Solid Biosciences coverage with Outperform rating
All SLDB news →About Solid Biosciences
Solid Biosciences develops gene-based medicines for uncommon inherited muscle and heart conditions. Its main programs target Duchenne muscular dystrophy, Friedreich's ataxia, a heart rhythm disorder called CPVT, and a form of heart muscle disease linked to the TNNT2 gene. The company's therapies use modified viruses to deliver working genes into muscle and heart cells. It runs clinical studies at sites in the United States, Canada, Europe and Australia.
Based on the company's 10-K filed Mar 19, 2026.
Nasdaq · Healthcare
Solid Biosciences Inc. (SLDB)
What Is the Price Target for SLDB?
SEPT Low Target
$16.00
SEPT Mid Target
$20.00
SEPT High Target
$26.00
Analyst Consensus
$20.00
Is SLDB a Buy or Sell Right Now?
Thesis
- •Revenue growing -40.6% YoY with UNKNOWN trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SLDB.
Start Free Trial →Is SLDB Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$16.70
12
Moat Score
NONE
3/9
Piotroski Score
-1.1
Altman Z-Score
What Is Smart Money Doing with SLDB?
Insider Signal
SELLING
0 buys / 17 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Brooks Gabriel | officer | Sale | 4,374 | $25K | Oct 19, 2026 |
| Brooks Gabriel | officer | Buy | 9,750 | - | Oct 18, 2026 |
| SMITH IAN F | director | Buy | 3,440 | - | Oct 2, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →SLDB Growth Story
Revenue YoY
-40.6%
3yr Revenue CAGR
N/A%
EPS Growth YoY
34.97%
FCF Growth YoY
-56.4%
Revenue Trend
UNKNOWN
Dark Pool Trades for SLDB
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for SLDB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:00 | $7.60 | 1,346 | $$10K | SELL |
| 20:39:30 | $7.61 | 1,100 | $$8K | BUY |
| 20:29:19 | $7.60 | 1,829 | $$14K | BUY |
| 19:41:38 | $7.62 | 1,000 | $$8K | BUY |
| 19:07:03 | $7.61 | 1,981 | $$15K | BUY |
5 dark pool trades shown · $$55K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Solid Biosciences Inc. (SLDB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SLDB — frequently asked questions
What is SLDB stock price today?
Solid Biosciences Inc. (SLDB) is at $7.60, up 6.00% (+$0.43) at the Nov 11, 2026 close.
Why is SLDB stock moving today?
Latest SLDB news — Nov 11, 2026: Circio and Solid Biosciences partner on gene therapy for genetic heart disease · Nov 11, 2026: Circio and Solid Biosciences team up on heart gene therapy research
Why did SLDB stock move on Oct 26, 2026?
Solid Biosciences received EU orphan designation for SGT-212, its treatment candidate for Friedreich's ataxia, and also reported continued progress in its FALCON trial. Despite these positive regulatory and clinical developments, the stock closed down 3.00% at $5.82, trading between $6.09 and $5.74 on volume of 747,579 shares.
What is the SLDB price target?
The average analyst price target for SLDB is $20.00, ranging from $16 to $26, based on 7 analysts. Latest: UBS initiates on Oct 15, 2026.
What do analysts rate SLDB?
Analyst ratings for SLDB: 0 Buy, 8 Hold, 0 Sell — consensus Hold.
Did SLDB beat earnings?
SLDB last reported on Aug 6, 2026: EPS -$0.38 vs -$0.46 expected — a beat of 17.8%.
Does SLDB pay a dividend?
SLDB does not currently pay a dividend.
What are SLDB support and resistance levels?
Support: $7.54, $6.65, $5.83. Resistance: $8.16, $9.03, $9.78.
What are insiders doing with SLDB?
Insider activity: SELLING, 0 buys and 17 sells in the last 90 days.
What is the latest news on SLDB?
Nov 11, 2026: Circio and Solid Biosciences partner on gene therapy for genetic heart disease · Nov 11, 2026: Circio and Solid Biosciences team up on heart gene therapy research · Nov 10, 2026: William Blair starts Solid Biosciences coverage with Buy rating